Vaxart, Inc. (VXRT)
| Market Cap | 187.80M |
| Revenue (ttm) | 237.26M |
| Net Income (ttm) | 16.33M |
| Shares Out | 241.17M |
| EPS (ttm) | 0.07 |
| PE Ratio | 11.12 |
| Forward PE | 2.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,087 |
| Average Volume | 356,703 |
| Open | 0.771 |
| Previous Close | 0.780 |
| Day's Range | 0.710 - 0.778 |
| 52-Week Range | 0.261 - 0.845 |
| Beta | 1.32 |
| RSI | 58.96 |
| Earnings Date | May 14, 2026 |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is... [Read more]
Financial Performance
Financial StatementsNews
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based...
Vaxart Transcript: Fireside chat
Management highlighted progress on clinical milestones, cost-saving initiatives, and global partnership efforts. The oral vaccine platform is positioned to address vaccine fatigue and global immunization needs, with key data readouts expected in 2026 and a cash runway into Q2 2027.
Vaxart Earnings Call Transcript: Q4 2025
Revenue surged to $237.3M in 2025, driven by BARDA and Dynavax deals, with cash runway into Q2 2027. Key COVID-19 and norovirus vaccine trials are progressing, with major data readouts expected in 2026 and significant milestone payments possible.
Vaxart to Host Upcoming Conference Calls
Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m.
Vaxart Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The oral pill vaccine platform offers both systemic and mucosal immunity, with ongoing phase IIb trials for COVID-19 and advanced programs in norovirus and influenza. Strategic partnerships, notably with Dynavax (now Sanofi), provide funding and validation, while upcoming data readouts and potential expansion into new indications are expected to drive growth.
Vaxart Transcript: Global BioInnovation Forum 2026
Oral pill vaccines are being developed to improve convenience, access, and immune response, with strong preclinical and clinical data supporting efficacy and safety. Key COVID-19 and norovirus trial results are expected in 2026, potentially marking major milestones.
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccine...
Vaxart Earnings Call Transcript: Q3 2025
Secured a transformative partnership with Dynavax for the oral COVID-19 vaccine, extending cash runway into Q2 2027 and validating the platform. Q3 revenue surged to $72.4 million, and robust progress was made in both COVID-19 and norovirus programs.
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors autho...
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continu...
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pil...
Vaxart Appoints W. Mark Watson as Lead Independent Director
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -
Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting
Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes
Vaxart Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A thermally stable oral pill vaccine platform is advancing programs for norovirus, COVID-19, and flu, with significant clinical progress and upcoming milestones including a phase 2B norovirus study and a large COVID-19 trial. The platform aims to address unmet needs and provide alternatives to traditional vaccines.
Vaxart Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and f...
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pi...
Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability
Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Sto...
Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights
Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board's Pattern of Disregarding Stockholders' Will and Value-Destructive Capital Alloc...
US orders Vaxart to stop COVID-19 trial amid mRNA wind down
Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, joining multiple biotech companies that have lost government funding for their ...
Vaxart Earnings Call Transcript: Q2 2025
Q2 2025 saw a major revenue increase from BARDA contracts, positive norovirus phase I data, and strong preclinical influenza results. COVID-19 trial enrollment halted at 5,000, with top-line data expected in 2026. Nasdaq relisting efforts continue amid cost controls and funding pursuits.
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Pane...
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pi...
Vaxart Transcript: AGM 2025
The meeting covered director elections, a failed reverse stock split proposal, and approval of the accounting firm. Management addressed shareholder questions on partnerships, capital strategy, and next steps after the reverse split vote.